National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2017

Tanja Y. Walker, MPH; Laurie D. Elam-Evans, PhD; David Yankey, PhD; Lauri E. Markowitz, MD; Charnetta L. Williams, MD; Sarah A. Mbaeyi, MD; Benjamin Fredua, MS; Shannon Stokley, DrPH

Disclosures

Morbidity and Mortality Weekly Report. 2018;67(33):909-917.

Abstract and Introduction

Introduction

The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination of persons aged 11–12 years with human papillomavirus (HPV) vaccine, quadrivalent meningococcal conjugate vaccine (MenACWY), and tetanus and reduced diphtheria toxoids and acellular pertussis vaccine (Tdap). A booster dose of MenACWY is recommended at age 16 years,^[1] and catch-up vaccination is recommended for hepatitis B vaccine (HepB), measles, mumps, and rubella vaccine (MMR), and varicella vaccine (VAR) for adolescents whose childhood vaccinations are not up to date (UTD).^[1] ACIP also recommends that clinicians may administer a serogroup B meningococcal vaccine (MenB) series to adolescents and young adults aged 16–23 years, with a preferred age of 16–18 years.^[2] To estimate U.S. adolescent vaccination coverage, CDC analyzed data from the 2017 National Immunization Survey–Teen (NIS-Teen) for 20,949 adolescents aged 13–17 years.* During 2016–2017, coverage increased for ≥1 dose of HPV vaccine (from 60.4% to 65.5%), ≥1 dose of MenACWY (82.2% to 85.1%), and ≥2 doses of MenACWY (39.1% to 44.3%). Coverage with Tdap remained stable at 88.7%. In 2017, 48.6% of adolescents were UTD with the HPV vaccine series (HPV UTD) compared with 43.4% in 2016.^† On-time vaccination (receipt of ≥2 or ≥3 doses of HPV vaccine by age 13 years) also increased. As in 2016, ≥1-dose HPV vaccination coverage was lower among adolescents living in nonmetropolitan statistical areas (MSAs) (59.3%) than among those living in MSA principal cities (70.1%).^§ Although HPV vaccination initiation remains lower than coverage with MenACWY and Tdap, HPV vaccination coverage has increased an average of 5.1 percentage points annually since 2013, indicating that continued efforts to target unvaccinated teens and eliminate missed vaccination opportunities might lead to HPV vaccination coverage levels comparable to those of other routinely recommended adolescent vaccines.

NIS-Teen is an annual survey that estimates vaccination coverage among adolescents aged 13–17 years in the 50 states, the District of Columbia (DC), selected local areas, and territories.^¶ NIS-Teen is conducted among parents and guardians of eligible adolescents identified using a random-digit–dialed sample of landline and cellular telephone numbers.** Parents and guardians are interviewed by telephone about the sociodemographic characteristics of the adolescent and household. Contact information and consent to contact the teen's vaccination providers are requested. When more than one age-eligible adolescent lives in the household, one is randomly selected for participation. Vaccination providers identified during the interview are mailed a questionnaire requesting the vaccination history from the teen's medical record.^†† Vaccination coverage estimates are based on provider-reported vaccination histories. This report summarizes national vaccination coverage for 20,949 adolescents (9,845 females [47%] and 11,104 males [53%]) aged 13–17 years with adequate provider data.^§§

Data were weighted and analyzed to account for the complex sampling design of NIS-Teen. NIS-Teen methodology, including methods for weighting and synthesizing provider-reported vaccination histories, has been described previously.^[3] T-tests were used to assess vaccination coverage differences between 2017 and 2016 and between demographic subgroups (i.e., age, health insurance status, MSA status, race/ethnicity, and poverty level). Weighted linear regression by survey year was used to estimate annual percentage point changes in coverage. Trends in HPV vaccination initiation and HPV UTD status by year of birth were assessed using combined data from 2016 and 2017 NIS-Teen; p-values <0.05 were considered statistically significant.

1 2 3 4 5

Next Section

Abstract and Introduction
National Vaccination Coverage
Vaccination Coverage by Selected Characteristics
State, Local, and Territorial Vaccination Coverage
Discussion
References
Sidebar

*Eligible participants were born during January 1999–February 2005. Tdap coverage represents receipt of ≥1 Tdap dose at age ≥10 years. MenACWY coverage represents receipt of the quadrivalent meningococcal conjugate vaccine or meningococcal vaccine of unknown type. MenB coverage represents receipt of at least 1 dose of either a 2-dose or 3-dose series, depending upon the vaccine brand. HPV vaccination coverage includes receipt of any HPV vaccine and does not distinguish between nine-valent (9vHPV), quadrivalent (4vHPV), or bivalent (2vHPV) vaccines. Some adolescents might have received more than the 2 or 3 recommended HPV vaccine doses. Estimates for hepatitis B and MMR vaccines represent coverage based on catch up for adolescents who were not up-to-date with these vaccinations. Except as noted, coverage estimates for ≥1 and ≥2 varicella vaccine doses were obtained among adolescents with no history of varicella disease. Influenza vaccination coverage data are not included in this report but are available online at https://www.cdc.gov/flu/fluvaxview/index.htm.
^†Adolescents were considered to be HPV UTD if they had received ≥3 doses, or if all of the following applied: 1) they had received 2 doses; 2) the first dose was received before the 15th birthday; and 3) the interval between the first and second doses was ≥5 months minus 4 days, the absolute minimum interval between the first and second doses. https://www.cdc.gov/vaccines/programs/iis/cdsi.html.
^§MSA status was determined based on household reported city and county of residence, and status was grouped into three categories: MSA principal city, MSA nonprincipal city, and non-MSA. MSA and principal city were as defined by the U.S. Census Bureau (https://www.census.gov/geo/reference/gtc/gtc_cbsa.html). Non-MSA areas include urban populations not located within an MSA as well as completely rural areas.
^¶The following local areas that received federal Section 317 immunization funds were sampled separately: Chicago, Illinois; New York, New York; Philadelphia County, Pennsylvania; Bexar County, Texas; and Houston, Texas. Three local areas were oversampled (Dallas County, Texas, El Paso County, Texas, and Travis County, Texas). Three territories were sampled separately in 2017 (Guam, Puerto Rico, and the U.S. Virgin Islands). Because of the severity of 2017's hurricane season, survey operations in Puerto Rico and the U.S. Virgin Islands were suspended resulting in insufficient data for estimation of vaccination coverage.
**All identified cellular-telephone households were eligible for interview. Sampling weights were adjusted for dual-frame (landline and cellular telephone), nonresponse, noncoverage, and overlapping samples of mixed telephone users. A description of NIS-Teen dual-frame survey methodology and its effect on reported vaccination estimates is available at https://www.cdc.gov/vaccines/imz-managers/coverage/nis/child/dual-frame-sampling.html. Starting in 2018, the landline telephone sample was dropped.
^††For the telephone samples for the states and local areas, the overall Council of American Survey Research Organizations (CASRO) response rate was 25.7% (51.5% for the landline sample and 23.5% for the cellular-telephone sample). For adolescents with completed interviews, 48.1% had adequate provider data (53.6% landline sample, 47.1% cell sample). Among completed interviews with adequate provider data, 17% (3,572) were from the landline sample, and 83% (17,377) were from the cellular telephone sample. For Guam, the overall CASRO response rate was 31.3%. The CASRO response rate is the product of three other rates: 1) the resolution rate (the proportion of telephone numbers that can be identified as either for business or residence); 2) the screening rate (the proportion of qualified households that complete the screening process); and 3) the cooperation rate (the proportion of contacted eligible households for which a completed interview is obtained).
^§§Adolescents from Guam (n = 382).

Table 1. Estimated vaccination coverage with selected vaccines and doses among adolescents aged 13–17* years, by age at interview — National Immunization Survey–Teen (NIS–Teen), United States, 2017
Vaccine	Age (yrs), % (95% CI)^†					Total, % (95% CI)^†
Vaccine	13(n = 4,283)	14(n = 4,429)	15(n = 4,212)	16(n = 4,218)	17(n = 3,807)	2017(n = 20,949)	2016(n = 20,475)
Tdap^§ ≥1 dose	86.4 (84.0–88.4)	89.9 (88.0–91.5)^¶	89.4 (87.7–91.0)^¶	89.7 (87.7–91.5)^¶	88.1 (85.4–90.3)	88.7 (87.8–89.6)	88.0 (87.1–88.9)
MenACWY**
≥1 dose	83.6 (81.2–85.8)	85.8 (83.8–87.6)	85.1 (83.1–86.9)	86.6 (84.5–88.4)	84.4 (81.7–86.8)	85.1 (84.2–86.1)^††	82.2 (81.2–83.2)
≥2 doses^§§	NA	NA	NA	NA	44.3 (41.4–47.2)	44.3 (41.4–47.2)^††	39.1 (36.1–42.1)
HPV^¶¶ vaccine – all adolescents
≥1 dose	60.7 (57.9–63.5)***	65.1 (62.5–67.6)^¶	66.5 (63.8–69.1)^¶	67.3 (64.7–69.8)^¶	68.1 (65.4–70.7)^¶	65.5 (64.3–66.7)^††	60.4 (59.2–61.6)
UTD^†††	39.0 (36.2–41.8)***	48.3 (45.5–51.2)^¶	50.7 (47.8–53.6)^¶	52.7 (49.8–55.5)^¶	52.5 (49.5–55.4)^¶	48.6 (47.3–49.9)^††	43.4 (42.1–44.7)
HPV^¶¶ vaccine – females
≥1 dose	64.5 (60.5–68.3)***	67.8 (63.8–71.6)	67.2 (63.4–70.9)	71.5 (67.8–75.0)^¶	72.0 (68.1–75.6)^¶	68.6 (66.9–70.2)^††	65.1 (63.3–66.8)
UTD	43.7 (39.6–47.8)***	52.7 (48.3–57.1)^¶	53.3 (49.1–57.5)^¶	57.5 (53.3–61.5)^¶	58.7 (54.2–63.1)^¶	53.1 (51.2–55.0)^††	49.5 (47.6–51.4)
HPV^¶¶ vaccine – males
≥1 dose	57.1 (53.1–61.0)	62.4 (59.1–65.6)^¶	65.7 (61.9–69.3)^¶	63.4 (59.7–67.0)^¶	64.3 (60.6–67.9)^¶	62.6 (60.9–64.2)^††	56.0 (54.3–57.7)
UTD	34.4 (30.8–38.2)	44.1 (40.6–47.6)^¶	48.1 (44.1–52.2)^¶	48.2 (44.3–52.1)^¶	46.4 (42.5–50.4)^¶	44.3 (42.6–46.0)^††	37.5 (35.8–39.2)
MMR ≥2 doses	93.7 (92.4–94.8)	91.6 (89.6–93.3)	92.1 (90.3–93.5)	91.6 (89.5–93.2)	91.3 (89.4–92.9)^¶	92.1 (91.3–92.8)^††	90.9 (90.1–91.6)
Hepatitis B vaccine ≥3 doses	93.0 (91.4–94.3)	92.4 (90.6–93.8)	91.6 (89.8–93.1)	90.9 (88.9–92.6)	91.7 (89.8–93.3)	91.9 (91.1–92.6)	91.4 (90.7–92.1)
Varicella vaccine
History of varicella disease^§§§	9.8 (8.2–11.7)	11.4 (10.0–13.1)	13.7 (11.6–16.1)^¶	14.9 (12.7–17.4)^¶	16.5 (14.6–18.6)^¶	13.2 (12.3–14.2)^††	15.2 (14.3–16.1)
No history of varicella disease
≥1 vaccine dose	96.7 (95.6–97.5)	95.7 (93.9–97.1)	95.5 (94.2–96.6)	94.4 (92.2–96.0)^¶	94.9 (92.8–96.5)	95.5 (94.8–96.1)	95.0 (94.2–95.6)
≥2 vaccine doses	92.0 (90.2–93.6)	90.2 (87.9–92.1)	88.8 (86.6–90.7)^¶	86.1 (83.7–88.2)^¶	85.4 (82.7–87.7)^¶	88.6 (87.6–89.5)^††	85.6 (84.5–86.6)
History of varicella disease or receipt of ≥2 varicella vaccine doses	92.8 (91.1–94.2)	91.3 (89.2–93.0)	90.3 (88.4–92.0)^¶	88.2 (86.1–90.0)^¶	87.8 (85.5–89.7)^¶	90.1 (89.3–90.9)^††	87.8 (86.9–88.6)

Abbreviations: CI = confidence interval; HPV = human papillomavirus; MenACWY = quadrivalent meningococcal conjugate vaccine; MMR = measles, mumps, and rubella vaccine; NA = not applicable, Tdap = tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine; UTD = up to date.
*Adolescents (N = 20,949) in the 2017 NIS–Teen were born January 1999 through February 2005.
^†Estimates with 95% CIs >20 might be unreliable.
^§Includes percentages receiving Tdap vaccine at age ≥10 years.
^¶Statistically significant difference (p<0.05) in estimated vaccination coverage by age; reference group was adolescents aged 13 years.
**Includes percentages receiving MenACWY or meningococcal vaccine of unknown type.
^††Statistically significant difference (p<0.05) compared with 2016 NIS-Teen estimates.
^§§≥2 doses of MenACWY or meningococcal vaccine of unknown type. Calculated only among adolescents who were aged 17 years at interview. Does not include adolescents who received one dose of MenACWY vaccine at age ≥16 years.
^¶¶HPV vaccine, nine–valent (9vHPV), quadrivalent (4vHPV), or bivalent (2vHPV). For ≥1-dose measure, percentages are reported among females and males combined (N = 20,949) and for females only (N = 9,845) and males only (N = 11,104).
***Statistically significant difference (p<0.05) in estimated vaccination coverage at age 13 years compared with 2016 NIS-Teen estimates.
^†††HPV UTD includes those with ≥3 doses, and those with 2 doses when the first HPV vaccine dose was initiated at age <15 years and at least 5 months minus 4 days elapsed between the first and second dose. This update to the HPV recommendation occurred in December of 2016.
^§§§By parent/guardian report or provider records.

Table 2. Estimated vaccination coverage with selected vaccines and doses among adolescents aged 13–17 years,* by poverty level ^† and metropolitan statistical area ^§ — National Immunization Survey–Teen (NIS-Teen), United States, 2017
Vaccine	Poverty status% (95% CI)^¶			Metropolitan statistical area (MSA)% (95% CI)^¶
Vaccine	Below poverty level(n = 3,579)	At or above poverty level(n = 16,591)	Difference(n = 20,170)	Non-MSA(n = 4,123)	MSA nonprincipal city(n = 8,282)	MSA principal city(n = 8,544)	Difference between non-MSA and MSA principal city(n = 12,667)	Difference between MSA nonprincipal city and principal city(n = 16,826)
Tdap ≥1 dose**	88.2 (85.7 to 90.4)	88.8 (87.7 to 89.7)	-0.6 (-3.0 to 2.0)	88.0 (86.0 to 89.8)	88.9 (87.5 to 90.1)	88.8 (87.2 90.1)	-0.8 (-3.1 to 1.6)	0.1 (-1.8 to 2.1)
MenACWY^††
≥1 dose	85.7 (83.2 to 87.8)	84.8 (83.7 to 85.8)	0.9 (-1.7 to 3.4)	78.6 (76.3 to 80.7)^§§	86.1 (84.6 to 87.4)	86.0 (84.4 to 87.4)	-7.4 (-10.0 to 4.7)^§§	0.1 (-81.2 to 83.2)
≥2 doses^¶¶	46.2 (38.6 to 54.0)	42.8 (39.7 to 45.9)	3.4 (-4.9 to 11.7)	35.0 (29.6 to 40.8)^§§	44.3 (40.2 to 48.5)	47.0 (42.2 to 51.9)	-12.0 (-19.5 to 4.6)^§§	-2.7 (-9.1 to 3.7)
HPV***
≥1 dose	73.3 (70.7 to 75.8)^§§	62.8 (61.4 to 64.1)	10.5 (7.6 to 13.5)^§§	59.3 (56.6 to 61.9)^§§	63.1 (61.3 to 64.8)^§§	70.1 (68.2 to 71.9)	-10.8 (-14.0 to 7.6)^§§	-7.0 (-9.6 to 4.4)^§§
UTD^†††	53.7 (50.7 to 56.6)^§§	46.7 (45.3 to 48.2)	7.0 (3.6 to 10.3)^§§	42.4 (39.8 to 45.1)^§§	46.9 (45.0 to 48.8)^§§	52.4 (50.3 to 54.4)	-10.0 (-13.3 to 6.6)^§§	-5.5 (-8.3 to 2.6)^§§
≥2 MMR doses	90.6 (88.4 to 92.5)	92.4 (91.5 to 93.1)	-1.8 (-3.9 to 0.5)	92.0 (90.6 to 93.3)	92.1 (90.9 to 93.1)	92.1 (90.7 to 93.3)	-0.1 (-1.9 to 1.8)	0.0 (-1.7 to 1.7)
≥3 Hepatitis B doses	89.9 (87.6 to 91.8)^§§	92.5 (91.7 to 93.3)	-2.6 (-4.8 to 0.3) ^§§	91.3 (89.6 to 92.7)	92.0 (90.9 to 93.0)	92.0 (90.6 to 93.1)	-0.7 (-2.7 to 1.3)	0.0 (-1.6 to 1.7)
Varicella
History of varicella disease^§§§	13.8 (12.1 to 15.6)	12.6 (11.6 to 13.6)	1.2 (-0.8 to 3.2)	16.1 (14.2 to 18.2)	12.2 (11.0 to 13.5)	13.6 (12.1 to 15.2)	2.5 (0.0 to 5.1)	-1.4 (-3.4 to 0.6)
No history of varicella disease
≥1 varicella vaccine dose	94.4 (91.9 to 96.1)	95.7 (95.0 to 96.4)	-1.3 (-3.5 to 0.8)	95.4 (94.1 to 96.5)	95.6 (94.6 to 96.5)	95.4 (94.0 to 96.4)	0.0 (-1.6 to 1.7)	0.2 (-1.3 to 1.8)
≥2 varicella vaccine doses	88.2 (85.5 to 90.4)	88.6 (87.6 to 89.6)	-0.4 (-3.1 to 2.2)	87.3 (85.4 to 89.1)	88.8 (87.4 to 90.1)	88.7 (87.0 to 90.2)	-1.4 (−3.8 to 1.1)	0.1 (-1.9 to 2.3)
History of varicella or receipt of ≥2 doses varicella vaccine	89.8 (87.5 to 91.7)	90.1 (89.1 to 90.9)	-0.3 (-2.6 to 2.0)	89.4 (87.7 to 90.8)	90.2 (88.9 to 91.3)	90.2 (88.7 to 91.5)	-0.8 (-2.9 to 1.3)	0.0 (-1.8 to 1.9)

Abbreviations: CI = confidence interval; HPV = human papillomavirus; MenACWY = quadrivalent meningococcal conjugate vaccine; MMR = measles, mumps, and rubella vaccine; Tdap = tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine; UTD = up-to-date.
*Adolescents (N = 20,949) in the 2017 NIS-Teen were born January 1999 through February 2005.
^†Adolescents were classified as below poverty level if their total family income was less than the federal poverty level specified for the applicable family size and number of children aged <18 years. All others were classified as at or above the poverty level. Additional information available at https://www.census.gov/data/tables/time-series/demo/income-poverty/historical-poverty-thresholds.html. Poverty status was unknown for 779 adolescents.
^§MSA status was determined based on household-reported county and city of residence, and was grouped into three categories: MSA principal city, MSA nonprincipal city, and non-MSA. MSA and principal city were as defined by the U.S. Census Bureau (https://www.census.gov/geo/reference/gtc/gtc_cbsa.html). Non-MSA areas include urban populations not located within an MSA as well as completely rural areas.
^¶Estimates with 95% CIs >20 might be unreliable.
**Includes percentages receiving Tdap vaccine at age ≥10 years.
^††Includes percentages receiving MenACWY and meningococcal vaccine of unknown type.
^§§Statistically significant difference (p<0.05) in estimated vaccination coverage by poverty level or metropolitan statistical area; the referent groups were adolescents living at or above poverty level and MSA principal city respectively.
^¶¶≥2 doses of MenACWY or meningococcal vaccine of unknown type vaccine. Calculated only among adolescents aged 17 years at interview. Does not include adolescents who received one dose of MenACWY vaccine at age ≥16 years.
***HPV vaccine, nine-valent (9vHPV), quadrivalent (4vHPV), or bivalent (2vHPV) in females and males combined.
^†††HPV UTD includes those with ≥3 doses and those with 2 doses when the first HPV vaccine dose was initiated at age <15 years and at least 5 months minus 4 days elapsed between the first and second dose. This update to the HPV recommendation occurred in December of 2016.
^§§§By parent/guardian report or provider records.

Table 3. Estimated vaccination coverage with selected vaccines and doses* among adolescents aged 13–17 years, ^† by HHS region, state, selected local area, or territory — National Immunization Survey–Teen (NIS-Teen), United States, 2017
Region, state, local area	All adolescents (N = 20,949)% (95% CI)^§
Region, state, local area	≥1 Tdap^¶	≥1 MenACWY**	≥1 HPV^††	HPV UTD^§§
United States overall	88.7 (87.8–89.6)	85.1 (84.2–86.1)^¶¶	65.5 (64.3–66.7)^¶¶	48.6 (47.3–49.9)^¶¶
Region I	94.6 (93.1–95.7)	92.5 (90.8–93.9)	78.2 (75.4–80.8)^¶¶	63.3 (60.1–66.4)^¶¶
Connecticut	94.9 (91.9–96.8)	94.9 (91.4–97.0)	71.3 (64.9–76.9)^¶¶	58.0 (51.4–64.3)
Maine	85.1 (79.8–89.3)	83.9 (78.8–88.0)	75.8 (70.2–80.6)	59.2 (53.2–65.0)
Massachusetts	96.2 (93.4–97.8)	94.0 (90.7–96.2)	81.9 (76.9–85.9)^¶¶	65.5 (59.7–70.8)^¶¶
New Hampshire	95.1 (91.6–97.2)	87.9 (82.9–91.6)	74.2 (68.5–79.2)	59.9 (53.7–65.8)
Rhode Island	94.6 (91.0–96.8)	94.1 (90.2–96.5)	88.6 (83.3–92.4)	77.7 (71.6–82.8)
Vermont	92.8 (89.2–95.2)	84.2 (78.9–88.3)	78.7 (73.2–83.3)^¶¶	64.5 (58.4–70.2)^¶¶
Region II	91.9 (89.7–93.7)	90.6 (88.1–92.6)	67.6 (64.1–71.0)	52.3 (48.5–56.0)
New Jersey	90.0 (85.3–93.3)	93.3 (89.4–95.9)	65.8 (59.8–71.3)	49.6 (43.4–55.8)
New York	92.9 (90.3–94.8)	89.3 (85.9–91.9)	68.5 (64.0–72.7)	53.6 (48.9–58.2)
New York – New York City	92.9 (89.0–95.5)	88.8 (83.6–92.6)	73.3 (66.9–78.9)	61.0 (54.1–67.5)
New York – rest of state	92.8 (89.1–95.4)	89.5 (84.9–92.9)	65.5 (59.3–71.2)	48.8 (42.6–55.0)
Region III	89.5 (87.0–91.6)	88.8 (86.3–91.0)^¶¶	70.3 (67.0–73.3)^¶¶	54.5 (51.0–57.9)^¶¶
Delaware	89.6 (84.5–93.2)	90.5 (85.7–93.7)	75.3 (69.3–80.5)	58.1 (51.6–64.4)
District of Columbia	86.1 (80.2–90.4)	91.3 (85.7–94.9)	91.9 (87.6–94.8)^¶¶	78.0 (71.1–83.6)^¶¶
Maryland	88.3 (82.2–92.5)	91.8 (86.5–95.1)^¶¶	69.2 (62.1–75.6)	52.9 (45.4–60.2)
Pennsylvania	90.6 (86.7–93.5)	93.4 (90.3–95.6)	67.3 (62.2–72.1)	52.5 (47.3–57.7)
Pennsylvania – Philadelphia	91.6 (87.4–94.5)	91.1 (86.8–94.1)	84.9 (80.0–88.7)	69.5 (63.5–75.0)
Pennsylvania – rest of state	90.5 (85.9–93.7)	93.7 (90.1–96.0)	65.0 (59.2–70.4)	50.3 (44.5–56.0)
Virginia	89.3 (83.2–93.4)	80.0 (72.6–85.7)	75.6 (68.4–81.6)^¶¶	59.0 (51.1–66.6)^¶¶
West Virginia	87.5 (82.8–91.0)	87.9 (83.1–91.5)	60.9 (54.6–66.9)	43.9 (37.7–50.2)
Region IV	90.9 (89.3–92.2)	82.2 (80.0–84.1)^¶¶	60.0 (57.3–62.6)^¶¶	43.0 (40.3–45.7)^¶¶
Alabama	88.7 (84.3–92.0)	78.3 (73.0–82.9)	58.0 (52.0–63.9)	40.3 (34.4–46.5)
Florida	91.1 (87.1–94.0)	80.2 (74.3–85.0)	59.8 (53.1–66.1)	42.3 (35.9–49.0)
Georgia	93.3 (89.3–95.9)	95.3 (91.9–97.3)	64.3 (57.5–70.6)	45.7 (39.1–52.5)
Kentucky	86.4 (81.7–90.0)	83.3 (78.3–87.4)	49.6 (43.5–55.6)	37.7 (32.1–43.7)
Mississippi	92.4 (88.6–95.0)^¶¶	63.0 (56.9–68.7)	49.6 (43.4–55.9)	28.8 (23.5–34.8)
North Carolina	91.9 (87.8–94.7)	84.8 (79.4–89.0)^¶¶	66.8 (60.4–72.6)^¶¶	51.9 (45.3–58.4)^¶¶
South Carolina	89.4 (84.5–92.8)^¶¶	78.6 (72.4–83.7)^¶¶	59.6 (52.7–66.0)^¶¶	42.7 (36.1–49.5)^¶¶
Tennessee	89.4 (84.8–92.8)	75.0 (68.5–80.6)	56.1 (49.3–62.6)	39.2 (32.8–46.1)
Region V	91.8 (90.4–93.0)	89.4 (87.8–90.7)^¶¶	65.5 (63.2–67.8)^¶¶	49.0 (46.5–51.4)^¶¶
Illinois	92.4 (89.4–94.6)	89.2 (85.9–91.8)^¶¶	66.1 (61.5–70.4)	50.4 (45.8–55.0)
Illinois – Chicago	90.5 (84.9–94.2)	90.9 (83.4–95.2)	81.9 (73.9–87.8)	66.6 (57.7–74.4)
Illinois – rest of state	92.8 (89.2–95.3)	88.9 (85.0–91.8)^¶¶	62.7 (57.4–67.7)	46.9 (41.7–52.2)
Indiana	95.1 (92.3–96.9)^¶¶	93.1 (89.0–95.8)	59.3 (52.8–65.5)^¶¶	40.8 (34.4–47.5)
Michigan	93.4 (89.2–96.0)	93.5 (89.4–96.1)	67.3 (61.1–73.0)	54.3 (47.9–60.6)
Minnesota	87.5 (82.2–91.4)	87.5 (82.4–91.3)	68.1 (61.9–73.7)^¶¶	46.9 (40.7–53.3)
Ohio	90.6 (86.9–93.3)	87.3 (83.4–90.4)^¶¶	64.1 (58.4–69.3)	47.0 (41.2–52.8)
Wisconsin	90.3 (85.8–93.5)	83.8 (78.4–88.2)	69.2 (63.0–74.8)	52.3 (45.8–58.7)
Region VI	85.0 (83.0–86.8)	84.4 (82.4–86.2)	59.7 (57.1–62.2)^¶¶	41.3 (38.9–43.8)^¶¶
Arkansas	92.4 (88.6–94.9)	91.7 (87.4–94.7)	61.1 (54.8–67.0)	35.2 (29.4–41.5)
Louisiana	90.1 (85.5–93.4)	89.0 (84.3–92.5)	69.1 (63.3–74.4)^¶¶	52.9 (46.5–59.1)^¶¶
New Mexico	85.5 (80.3–89.5)	78.0 (72.4–82.8)	66.9 (60.9–72.4)	48.3 (42.2–54.5)
Oklahoma	86.7 (81.7–90.5)	71.1 (64.9–76.6)	58.5 (52.1–64.6)	41.4 (35.3–47.8)
Texas	83.2 (80.4–85.7)	85.1 (82.4–87.5)	57.8 (54.3–61.2 ^¶¶	39.7 (36.5–43.0)^¶¶
Texas – Bexar County	83.7 (77.8–88.3)	86.0 (80.3–90.3)	62.9 (56.6–68.8)^¶¶	46.4 (40.2–52.7)
Texas – Houston	87.9 (80.2–92.9)	91.4 (85.1–95.2)	73.0 (63.9–80.4)	55.2 (45.9–64.2)
Texas – Dallas County	77.0 (69.8–83.0)	85.1 (78.8–89.7)	54.5 (46.9–62.0)	35.7 (28.8–43.1)^¶¶
Texas – El Paso County	89.6 (84.8–93.0)	89.5 (84.4–93.0)	82.8 (77.2–87.2)	60.0 (52.9–66.6)
Texas – Travis County	85.9 (80.9–89.8)	89.1 (84.4–92.4)	69.7 (63.3–75.4)	52.0 (45.4–58.5)
Texas – rest of state	83.1 (79.3–86.3)	84.1 (80.4–87.2)	54.5 (49.9–59.1)^¶¶	36.6 (32.4–41.0)
Region VII	86.8 (84.0–89.2)	77.3 (74.2–80.2)^¶¶	61.5 (58.0–64.8)^¶¶	44.2 (40.9–47.6)
Iowa	93.4 (89.8–95.8)	83.6 (78.4–87.7)^¶¶	71.4 (65.6–76.5)^¶¶	53.7 (47.6–59.8)
Kansas	89.7 (84.9–93.1)	72.1 (65.8–77.6)	52.4 (46.0–58.8)	34.4 (28.6–40.7)
Missouri	80.1 (74.1–85.0)	74.3 (68.3–79.5)	57.8 (51.3–64.0)	39.6 (33.6–45.9)
Nebraska	92.3 (87.5–95.4)	84.8 (79.4–89.0)	71.0 (64.8–76.5)	58.3 (51.9–64.5)^¶¶
Region VIII	89.1 (86.6–91.1)	81.4 (78.7–83.8)^¶¶	65.7 (62.4–68.8)^¶¶	46.8 (43.4–50.3)^¶¶
Colorado	88.6 (83.6–92.2)	82.4 (77.2–86.6)	72.1 (66.2–77.3)	53.8 (47.4–60.0)
Montana	90.4 (85.8–93.7)	71.2 (64.9–76.8)	65.5 (58.9–71.5)^¶¶	49.1 (42.5–55.7)
North Dakota	90.6 (86.8–93.5)	91.9 (88.3–94.4)	72.5 (67.0–77.4)	57.8 (51.9–63.5)
South Dakota	79.5 (73.6–84.4)	74.5 (68.4–79.9)^¶¶	63.2 (56.7–69.2)	44.8 (38.5–51.2)
Utah	91.6 (87.7–94.3)^¶¶	85.1 (80.3–88.9)^¶¶	58.8 (52.6–64.8)	37.4 (31.5–43.7)
Wyoming	86.4 (81.2–90.3)	60.7 (54.5–66.6)	46.9 (40.8–53.1)	30.9 (25.5–36.8)
Region IX	83.3 (78.5–87.2)	82.2 (77.4–86.2)	70.4 (65.4–75.0)	53.1 (47.5–58.7)
Arizona	82.4 (76.7–87.0)	83.8 (78.3–88.1)	65.0 (58.4–71.2)	53.0 (46.3–59.6)
California	83.5 (77.2–88.3)	82.2 (75.9–87.1)	71.9 (65.4–77.5)	53.4 (46.3–60.4)
Hawaii	84.8 (79.3–89.1)	85.9 (80.6–90.0)^¶¶	69.4 (63.0–75.1)	54.7 (48.2–61.0)
Nevada	82.5 (76.6–87.1)	77.3 (71.0–82.5)	64.9 (58.3–70.9)	49.0 (42.6–55.5)
Region X	87.2 (84.5–89.5)	81.4 (78.2–84.2)^¶¶	69.9 (66.3–73.3)^¶¶	52.8 (48.9–56.6)^¶¶
Alaska	78.9 (73.2–83.6)	68.4 (62.5–73.8)	64.5 (58.4–70.1)	42.6 (36.7–48.8)
Idaho	87.3 (82.1–91.1)	90.5 (85.6–93.9)	62.4 (55.7–68.6)	44.1 (37.6–50.7)
Oregon	86.3 (81.6–90.0)	77.0 (71.5–81.8)	71.2 (65.4–76.4)^¶¶	54.8 (48.6–60.8)
Washington	88.6 (83.8–92.1)	82.6 (77.2–87.0)	71.9 (65.8–77.3)	55.2 (48.8–61.5)
Range***	(78.9–96.2)	(60.7–95.3)	(46.9–91.9)	(28.8–78.0)
Territory
Guam	77.3 (71.6–82.1)	68.3 (62.2–73.9) ^†††	67.5 (61.4–73.0)	42.7 (36.9–48.8)

Abbreviations: CI = confidence interval; HHS = U.S. Department of Health and Human Services; HPV = human papillomavirus; MenACWY = quadrivalent meningococcal conjugate vaccine; MMR = measles, mumps, rubella vaccine; Tdap = tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine; UTD = up-to-date.
*Estimates for additional measures, including MMR, hepatitis B, and varicella vaccines are available at https://www.cdc.gov/vaccines/vaxview/teenvaxview.
^†Adolescents (N = 20,949) in the 2017 NIS-Teen were born January 1999 through February 2005.
^§Estimates with 95% CIs >20 might be unreliable.
^¶≥1 dose Tdap vaccine at age ≥10 years.
**≥1 dose of MenACWY or meningococcal-unknown type vaccine.
^††HPV vaccine, nine-valent (9vHPV), quadrivalent (4vHPV), or bivalent (2vHPV) in females and males combined.
^§§HPV UTD includes those with ≥3 doses and those with 2 doses when the first HPV vaccine dose was initiated before age 15 years and there was at least 5 months minus 4 days between the first and second dose. This update to the HPV recommendation occurred in December of 2016.
^¶¶Statistically significant (p<0.05) percentage point increase compared to 2016.
***The calculation for the range was limited to the 50 states and the District of Columbia.
^†††Statistically significant (p<0.05) percentage point decrease from 2016.

Comments

processing....

National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2017

Abstract and Introduction

Introduction

Comments

Most Popular Articles

What to Read Next on Medscape

Special Coverage: COVID-19

About

Membership

Apps

WebMD Network

Editions

National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2017

Abstract and Introduction

Introduction

Tables

Tables

Tables

References

Authors and Disclosures

Authors and Disclosures

Sidebar

Sidebar

Summary

Comments

Most Popular Articles

What to Read Next on Medscape

Special Coverage: COVID-19

More from This Journal

Latest News & Perspective

Recommended Reading

Drugs Related to Pediatric Respiratory Infections

Most Popular Articles

Recommendations

Email This

Find Us On

About

Membership

Apps

WebMD Network

Editions